Department of Anesthesiology and Intensive Care, Medical University of Lublin, 20-954 Lublin, Poland.
Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 71-204 Szczecin, Poland.
Curr Neuropharmacol. 2021;19(8):1164-1177. doi: 10.2174/1570159X18666201119155535.
A traumatic brain injury (TBI) initiates an inflammatory response with molecular cascades triggered by the presence of necrotic debris, including damaged myelin, hemorrhages and injured neuronal cells. Molecular cascades prominent in TBI-induced inflammation include the release of an excess of proinflammatory cytokines and angiogenic factors, the degradation of tight junctions (TJs), cytoskeletal rearrangements and leukocyte and protein extravasation promoted by increased expression of adhesion molecules. The brain-gut axis consists of a complex network involving neuroendocrine and immunological signaling pathways and bi-directional neural mechanisms. Importantly, modifying the gut microbiome alters this axis, and in turn may influence brain injury and neuroinflammatory processes. In recent years it has been demonstrated that the activity and composition of the gastrointestinal (GI) microbiome population influences the brain through all of above-mentioned pathways affecting homeostasis of the central nervous system (CNS). The GI microbiome is involved in the modulation of cellular and molecular processes which are fundamental to the progression of TBI-induced pathologies, including neuroinflammation, abnormal blood brain barrier (BBB) permeability, immune system responses, microglial activation, and mitochondrial dysfunction. It has been postulated that interaction between the brain and gut microbiome occurs mainly via the enteric nervous system and the vagus nerve through neuroactive compounds including serotonin or dopamine and activation by bacterial metabolites including endotoxin, neurotransmitters, neurotrophic factors, and cytokines. In recent years the multifactorial impact of selected immunomodulatory drugs on immune processes occurring in the CNS and involving the brain-gut axis has been under intensive investigation.
创伤性脑损伤(TBI)引发炎症反应,分子级联反应由坏死碎片(包括受损髓鞘、出血和受损神经元细胞)引发。TBI 诱导的炎症中主要的分子级联反应包括过度释放促炎细胞因子和血管生成因子、紧密连接(TJ)降解、细胞骨架重排以及通过粘附分子表达增加促进白细胞和蛋白质渗出。脑-肠轴由涉及神经内分泌和免疫信号通路以及双向神经机制的复杂网络组成。重要的是,改变肠道微生物组会改变这个轴,进而可能影响脑损伤和神经炎症过程。近年来,已经证明胃肠道(GI)微生物组的活性和组成通过上述所有途径影响大脑,从而影响中枢神经系统(CNS)的内环境稳定。GI 微生物组参与调节细胞和分子过程,这些过程是 TBI 诱导的病理学进展的基础,包括神经炎症、异常血脑屏障(BBB)通透性、免疫系统反应、小胶质细胞激活和线粒体功能障碍。人们推测,大脑和肠道微生物组之间的相互作用主要通过肠神经系统和迷走神经通过神经活性化合物(如血清素或多巴胺)以及细菌代谢物(如内毒素、神经递质、神经营养因子和细胞因子)的激活发生。近年来,人们对免疫调节药物对涉及脑-肠轴的中枢神经系统中发生的免疫过程的多因素影响进行了深入研究。